Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis

PURPOSE: Fenebrutinib (GDC-0853), a Bruton’s tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was to apply a model-informed drug development (MIDD) approach to examine the totality of available clinical efficacy data. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Phyllis, Yu, Jiajie, Chinn, Leslie, Prohn, Marita, Huisman, Jan, Matzuka, Brett, Hanley, William, Tuckwell, Katie, Quartino, Angelica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944649/
https://www.ncbi.nlm.nih.gov/pubmed/31907670
http://dx.doi.org/10.1007/s11095-019-2752-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944649/
https://www.ncbi.nlm.nih.gov/pubmed/31907670
http://dx.doi.org/10.1007/s11095-019-2752-y

Ejemplares similares